Louis C. Drapeau
Director/Board Member bei Surface Ophthalmics, Inc.
Profil
Louis C.
Drapeau is an Independent Director at Surface Ophthalmics, Inc. He previously served as an Independent Director at Bio-Rad Laboratories, Inc., AmpliPhi Biosciences Corp., InterMune, Inc., EACOM Timber Corp., Bionovo, Inc., AVITA Medical Pty Ltd., AVITA Medical, Inc., and VP, Chief Financial & Accounting Officer at InSite Vision, Inc. He was also a Senior Vice President at Nektar Therapeutics and Chief Financial Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. Prior to his work in the pharmaceutical industry, he was an Audit Partner at Arthur Andersen LLP.
Drapeau received his undergraduate degree and MBA from Stanford University.
Aktive Positionen von Louis C. Drapeau
| Unternehmen | Position | Beginn |
|---|---|---|
Surface Ophthalmics, Inc.
 Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | Director/Board Member | - |
Ehemalige bekannte Positionen von Louis C. Drapeau
| Unternehmen | Position | Ende |
|---|---|---|
| AVITA MEDICAL, INC. | Director/Board Member | 29.04.2022 |
AVITA Medical Pty Ltd.
 AVITA Medical Pty Ltd. BiotechnologyHealth Technology Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company is headquartered in Valencia, CA. | Director/Board Member | 29.04.2022 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director/Board Member | 01.05.2019 |
| BIO-RAD LABORATORIES, INC. | Director/Board Member | 25.04.2017 |
| INSITE VISION INC. | Chief Executive Officer | 01.12.2010 |
Ausbildung von Louis C. Drapeau
| Stanford University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BIO-RAD LABORATORIES, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| AVITA MEDICAL, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
InSite Vision, Inc.
 InSite Vision, Inc. Pharmaceuticals: MajorHealth Technology InSite Vision Inc. develops and markets ophthalmic pharmaceutical products that designs to treat a range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Its products include AzaSite, Besivance, AzaSite Plus, DexaSite, AzaSite Xtra, and ISV-10 and 303. The company was founded by Merwin Jerry Hansen in 1986 and is headquartered in Alameda, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
EACOM Timber Corp.
 EACOM Timber Corp. Forest ProductsNon-Energy Minerals EACOM Timber Corp. engages in the manufacture and distribution of lumber and wood-based products, and the management of forest resources. It offers stud grade lumber, dimension lumber, machine-stress rated lumber, specialty lumber and engineered woods. The company was founded by Hassan Salari on April 2, 1980 and is headquartered in Montreal, Canada. | Non-Energy Minerals |
Bionovo, Inc.
 Bionovo, Inc. Pharmaceuticals: MajorHealth Technology Bionovo, Inc. is a clinical drug discovery and development company, which is focused on developing drugs for the treatment of unmet medical needs in women's health and cancer. The company was founded by Isaac Cohen and Mary Tagliaferri in February 2002 and is headquartered in Emeryville, CA. | Health Technology |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
AVITA Medical Pty Ltd.
AVITA Medical Pty Ltd. BiotechnologyHealth Technology Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company is headquartered in Valencia, CA. | Health Technology |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | Health Technology |
